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Abstract
Aim: We aimed to clarify the usefulness of procalcitonin (PCT) in the evaluation of histological chorioamnio-
nitis (CAM) and in the prediction of neonatal and infantile outcomes as a reference of interleukin-6 (IL-6).
Methods: Subjects were 36 singleton pregnant women delivered at 22–37 weeks’ gestation due to threatened
premature delivery and/or preterm premature rupture of membranes. Cases were classified into the CAM
and non-CAM groups, according to Blanc’s criteria. Comparisons were made on umbilical venous and amni-
otic fluid PCT levels among the groups. The relations between umbilical venous PCT and IL-6 levels and
neonatal and infantile outcomes were also analyzed.
Results: The umbilical venous PCT level in the CAM group (240.2 pg/mL, 125.4–350.3 pg/mL: median,
first quartile–third quartile) was higher than that in the non-CAM group (105.1, 50.2–137.5 pg/mL;
P = 0.0006). There were no differences in the amniotic fluid PCT levels between the groups. There was a
strong correlation between umbilical venous PCT and IL-6 levels (correlation coefficient: 0.793). Among
10 cases with an umbilical venous PCT level of ≥170.0 pg/mL and six cases with IL-6 ≥ 11.0 pg/mL, six
(60.0%) and five cases (83.3%), respectively, had adverse neonatal and infantile outcomes. Among seven
cases with adverse neonatal and infantile outcomes, six (85.7%) and five (71.4%) cases showed umbilical
venous PCT levels of ≥170.0 pg/mL and IL-6 levels of ≥11.0 pg/mL, respectively.
Conclusion: Similar to IL-6, the umbilical venous PCT level is a promising parameter for predicting histolog-
ical CAM and adverse neonatal and infantile outcomes related to in utero inflammatory status.
Key words: chorioamnionitis, interleukin-6, neonatal and infantile outcomes, procalcitonin, umbilical venous
blood.
Introduction
Preterm birth is one of the most significant factors for
morbidity and mortality in infants among developed
countries, including Japan. The prediction and pre-
vention of preterm birth is a crucial issue to be solved
in the current perinatal clinical setting. Chorioamnio-
nitis (CAM) is the leading cause of preterm birth, and
fetal inflammatory response associated with CAM
leads to devastating outcomes after birth, including
periventricular leukomalacia and chronic lung
diseases.1–6
CAM is diagnosed by pathological examination of
fetal membranes, which keep the integrity of the
fetus. The severity of histological CAM is determined
by Blanc’s criteria, based on the degree of inflamma-
tory cell infiltration, extending from the chorion to the
amnion, and further invading into the amniotic fluid.7
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The more inflammatory cell infiltration advances, the
more fetal hypercytokinemia is likely to be indicated.
There is a strong correlation between the presence of
CAM, and neonatal morbidity and mortality. Evaluat-
ing CAM at birth is, therefore, essential to predicting
neonatal outcome. Histological examination, however,
is time-consuming.
Procalcitonin (PCT) is a peptide precursor of calcito-
nin composed of 116 amino acids, and PCT levels rise
in response to a proinflammatory stimulus, especially
of bacterial origin. PCT observation has been clinically
available on an in-house test basis, as one of the bio-
markers for the diagnosis of sepsis, with high accuracy
and an ability to determine prognosis and therapeutic
effects. However, to date, few studies have been done
using PCT evaluation for the diagnosis of CAM. The
aim of this study was to clarify the usefulness of PCT
in diagnosing and evaluating of histological CAM,
and predicting neonatal and infantile outcome, while
referencing interleukin-6 (IL-6), the standard bio-
marker of fetal inflammatory response.
Methods
The subjects were 36 singleton pregnant women with
no fetal complications, who delivered at 22–37 weeks’
gestation at Kurume University Hospital due to
threatened premature delivery and/or preterm pre-
mature rupture of membranes (pPROM) between
April 2012 and March 2016. This study was con-
ducted with the approval of the Institutional Review
Board of our hospital (#12008) and all patients gave
written informed consent to participate in this study.
For each case, an umbilical venous blood sample
was collected at delivery for measurements of white
blood cell (WBC) count, C-reactive protein (CRP),
immunoglobulin M (IgM), PCT, and IL-6 levels.
Amniotic fluid was also taken at delivery for mea-
surement of the PCT level. Except for WBC count,
collected samples were centrifuged at 1,670 g for
15 min and plasma from the umbilical venous blood
and supernatant from the amniotic fluid were col-
lected and cryopreserved at −80C until analysis. PCT
and IL-6 were assayed using the Ray Bio, Inc. ELISA
kit and R&D System ELISA kit, respectively, and
quantified using the Bio Rad 680 microplate reader.
The lower limits for detection of PCT and IL-6
were 30.0 and 0.7 pg/mL, respectively. When the
values were less than the detection limit, the concen-
trations of PCT and IL-6 were represented as 30.0 and
0.7 pg/mL, respectively. The placenta was histologi-
cally diagnosed by qualified pathologists.
CAM was diagnosed using Blanc’s criteria as stages
I to III. Cases were classified into two groups – CAM
and non-CAM – as cases with CAM stage II or more
and cases with CAM stage I or negative. There were
16 and 20 cases in the CAM and non-CAM groups,
respectively. As for maternal background, there were
no significant differences except in the percentages of
cases with cesarean delivery (Table 1). As for neonatal
background, there were no differences except for 1-
min Apgar score and percentage of cases with chronic
lung disease. Parameters of clinical chorioamnionitis,
including maternal body temperature, maternal WBC
counts, CRP values, and fetal heart rate patterns on
cardiotocogram, were carefully monitored. Pregnan-
cies were terminated for reasons including tocolysis
failure, abnormal fetal heart rate monitoring, and
exacerbation of infection.
Comparisons were made on WBC count, CRP, IgM,
and PCT and IL-6 levels in umbilical venous blood
and amniotic fluid between the CAM and non-CAM
groups. In addition, the relations between the umbili-
cal venous PCT and IL-6 levels and between umbilical
venous PCT/IL-6 levels and neonatal and infantile
outcomes, including death up to 28 days/ 1 year after
birth, chronic lung disease, periventricular leukomala-
cia, and necrotizing enterocolitis, were analyzed.
The Mann–Whitney U-test and Fisher’s exact test
were used for inter-group comparisons. The Spear-
man’s rank-order correlation was used for correlation
analysis. The significance was set at P < 0.05. All ana-
lyses were conducted using JMP 10.0 (SAS Insti-
tute Inc.).
All procedures followed were in accordance with
the ethical standards of the responsible committee on
human experimentation (institutional and national)
and with the Helsinki Declaration of 1964 and later
versions. Informed consent was obtained from all
patients included in the study.
Results
There were no differences in WBC count, CRP, or
IgM levels in the umbilical venous blood between the
groups (Table 2). The umbilical venous PCT levels in
the CAM group (240.2 pg/mL, 125.4–350.3 pg/mL:
median, first quartile–third quartile) were higher than
those in the non-CAM group (105.1 pg/mL,
50.2–137.5 pg/mL; P = 0.0006; Fig. 1). The umbilical
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venous IL-6 levels in the CAM group (7.0 pg/mL,
1.25–37.5 pg/mL) were higher than those in the non-
CAM group (0.7 pg/mL, 0.7–2.1 pg/mL; P = 0.0006;
Fig. 2).
Amniotic fluid PCT levels of the CAM group
(40.3 pg/mL, 30.1–67.5 pg/mL) were not different
from those of the non-CAM group (65.8 pg/mL,
35.3–92.5 pg/mL; P > 0.05; Fig. 3).
There was a strong correlation between umbilical
venous PCT and IL-6 levels with a correlation coeffi-
cient of 0.793 (Fig. 4). Moreover, among the 16 cases
in the CAM group, PCT levels in the umbilical vein
were highly correlated with IL-6 levels (correlation
coefficient: 0.883). The receiver–operator curve for dis-
crimination between the CAM and non-CAM groups
revealed the cut-off PCT value of 170.0 pg/mL (area
under curve: 0.836). Ten (62.5%) out of 16 cases in the
CAM group showed a PCT level of ≥170.0 pg/mL
(Fig. 5). On the other hand, none of the 20 cases in the
non-CAM group indicated either PCT level of
<170.0 pg/mL, or IL-6 level of <11.0 pg/mL, which is
the criteria for fetal inflammatory response syndrome
(data not shown).
We further examined seven cases with adverse neo-
natal and infantile outcomes. There were six cases
and one case in the CAM and non-CAM groups,
respectively (Table 3). Five cases in the CAM group
(cases 1–5) demonstrated high umbilical PCT levels of
≥170.0 pg/mL and high IL-6 levels of ≥11.0 pg/mL.
One case in the CAM group (case 6) showed a high
Table 1 Perinatal characteristics of the CAM and non-CAM groups
CAM Non-CAM P-value
(n = 16) (n = 20)
Maternal
Age (years)† 31.0  1.2 31.0  1.2 NS
Primipara 11 (68.8%) 18 (90.0%) NS
Cesarean delivery 8 (50.0%) 16 (80.0%) 0.0379
Reasons for delivery
Tocolysis failure 14 (87.5%) 17 (85.0%) NS
Non-reassuring fetal status 0 (0.0%) 1 (5.0%) NS
Exacerbation of infection 2 (12.5%) 0 (0.0%) NS
Pre-eclampsia 0 (0.0%) 2 (10.0%) NS
Neonatal/infantile
Gestational age at delivery (weeks) † 33.3  2.6 33.3  0.7 NS
Birthweight (g) † 1653  140 1881  126 NS
Sex (male/female) 7/9 11/9 NS
1-min Apgar score† 5.5  2.0 7.4  1.7 0.0063
5-min Apgar score† 7.8  1.4 8.6  0.3 NS
Umbilical arterial pH† 7.36  0.07 7.32  0.02 NS
Duration of NICU admission (days)† 7.3  3.3 3.8  2.6 NS
Duration of respiratory support‡ (days)† 8.1  2.6 7.4  1.7 NS
Adverse neonatal/infantile outcomes
Death up to and including at 28 days 0 (0.0%) 0 (0.0%) NS
Death up to 1 year after birth 0 (0.0%) 0 (0.0%) NS
Chronic lung disease 5 (31.3%) 1 (5.0%) 0.0357
Periventricular leukomalacia 1 (6.2%) 0 (0.0%) NS
Necrotizing enterocolitis 1 (6.2%) 0 (0.0%) NS
†Data are shown as mean  standard deviation; ‡Mechanical ventilation, including intermittent mandatory ventilation, nasal continuous
airway pressure, and nasal directional airway pressure. CAM, chorioamnionitis; NICU, neonatal intensive care unit; NS, not significant.
Table 2 Inflammatory markers in umbilical venous blood in the CAM and non-CAM groups
CAM Non-CAM P-value
(n = 16) (n = 20)
White blood cell (/μL) 10 750 (9175–14 450) 8850 (7600–10 350) NS
C-reactive protein (mg/dL) 0.04 (0.04–0.09) 0.04 (0.04–0.04) NS
IgM (mg/mL) 6.00 (4.00–7.75) 6.50 (4.75–9.00) NS
Data are shown as median (first quartile–third quartile). CAM, chorioamnionitis; IgM, immunoglobulin M; NS, not significant.
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umbilical venous PCT level but low IL-6 level. One
case in the non-CAM group (case 7) had low umbili-
cal venous PCT and IL-6 levels. Among the 10 cases
with an umbilical venous PCT level of ≥170.0 pg/mL,
six (60.0%) had adverse neonatal and infantile out-
comes (Fig. 5), whilst among the six cases with umbil-
ical venous IL-6 level of ≥11.0 pg/mL, five cases
(83.3%) had adverse neonatal and infantile outcomes.
On the other hand, among 26 cases with umbilical
venous PCT levels of <170.0 pg/mL, only one case at
26 weeks’ gestation (3.8%) had an adverse neonatal
and infantile outcome, while among 29 cases with
umbilical venous IL-6 level of <11.0 pg/mL, two
cases (6.9%) had adverse neonatal and infantile
outcomes.
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Figure 1 Comparisons of umbilical venous procalcito-
nin levels in the chorioamnionitis (CAM) and non-
CAM groups. Boxes represent interquartile range
(IQR), interior lines median, whiskers are maxim and
minima within 1.5 × IQR.
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Figure 2 Comparisons of umbilical venous interleukin-
6 levels in the chorioamnionitis (CAM) and non-CAM
groups. Boxes represent interquartile range (IQR),
interior lines median, whiskers are maxim and min-
ima within 1.5 × IQR.
Figure 3 Comparisons of amniotic fluid procalcitonin
levels in the chorioamnionitis (CAM) and non-CAM
groups. Boxes represent interquartile range (IQR),
interior lines median, whiskers are maxim and min-
ima within 1.5 × IQR. NS, not significant.
Figure 4 Correlation of umbilical venous blood
between procalcitonin and interleukin-6 levels in the
(closed circle) chorioamnionitis (CAM) and (open cir-
cle) non-CAM groups. Dotted and dashed lines indi-
cate the regression lines between umbilical venous
procalcitonin and interleurin-6 levels overall and the
CAM group, respectively. Dotted line indicates the
cut-off procalcitonin value of 170.0 pg/mL.
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Discussion
Sepsis and CAM are among the most devastating
causes of neonatal morbidity and mortality, and the
prediction and early diagnosis of neonatal sepsis and
CAM are very important for neonatal care.8–10 To
date, several reports have been made on the useful-
ness of umbilical venous PCT, mainly for two pur-
poses: the prediction of neonatal sepsis11–13 and the
early diagnosis of CAM.14,15 Oludag et al. reported
that sensitivity and specificity of the umbilical venous
PCT level to predict CAM in cases with pPROM were
92.3% and 68.4%, respectively, in preterm neonates.14
Janota et al. reported that the umbilical venous PCT
level had a relation with CAM and neonatal sepsis.15
Moreover, umbilical venous PCT level had higher
sensitivity than umbilical venous CRP level. How-
ever, no reports have been made regarding the
relation between umbilical venous PCT and severity
of histological CAM, or between PCT and IL-6 level,
one of the most representative biomarkers for fetal
inflammatory response.
In this study, we demonstrated that umbilical venous
PCT levels increased along with histological CAM.
PCT, having a molecular weight of 11.4–11.6 kDa, can-
not cross the placenta. PCT detected in the umbilical
venous blood is considered to have originated in the
fetus. The gestational age at delivery in the CAM group
was earlier than that in the non-CAM group. Guibour-
denche et al. reported that in infants born prematurely
without intrauterine infection, umbilical cord venous
PCT levels were unrelated to gestational age at deliv-
ery.16 Therefore, elevated umbilical cord PCT levels in
the CAM group are not considered as being influenced
by gestational age, but rather reflecting the status of
intrauterine infection and inflammation.
There have been few reports regarding the useful-
ness of amniotic fluid PCT in predicting intrauterine
inflammation. Dulay et al. reported that they were
unable to diagnose intrauterine inflammation in utero
with amniotic fluid PCT obtained by amniocentesis.17
Torbé et al. stated that PCT in vaginal discharge in
cases with pPROM could not predict CAM or intra-
uterine infection.18,19 In this study, we also found that
amniotic fluid PCT was unrelated to the presence of
histological CAM. As amniotic fluid is mainly pro-
duced by fetal urine, it was assumed that the amniotic
fluid PCT level parallels the umbilical venous PCT
level; however, this was not the case.20,21 We specu-
late that in cases with CAM, fetal renal function is
impaired, which may result in a decrease of PCT
excretion into fetal urine and amniotic fluid.
In this study, a bacterial culture of the amniotic fluid
obtained by sterile methods was not performed in every
case for detecting the presence of intrauterine infection
of bacterial origin. Although fetal inflammatory
Figure 5 Relation between gestational age at delivery
and umbilical venous procalcitonin levels in the
(closed circle) chorioamnionitis (CAM) and (open cir-
cle) non-CAM groups. CLD, chronic lung disease;
NEC, necrotizing enterocolitis; PVL, periventricular
leukomalacia.
Table 3 Clinical characteristics of cases with adverse neonatal/infantile outcomes and umbilical procalcitonin and
interleukin-6 levels in the CAM and non-CAM groups
Case
no.
Adverse neonatal/
infantile outcome
Gestational
age at delivery
(weeks+days)
Birthweight
(g)
Umbilical venous
procalcitonin
level (pg/mL)
Umbilical venous
interleukin-6
level (pg/mL)
Group
1 PVL 33+3 1926 233.1 33.5 CAM
2 CLD 31+1 1750 301.4 17.1 CAM
3 CLD 27+3 1428 353.1 39.1 CAM
4 CLD/NEC 26+4 851 412.2 48.6 CAM
5 CLD 25+1 830 411.3 86.2 CAM
6 CLD 26+6 1192 303.2 0.7 CAM
7 CLD 25+3 682 50.3 0.7 Non-CAM
CAM, chorioamnionitis; CLD, chronic lung disease; NEC, necrotizing enterocolitis; PVL, periventricular leukomalacia.
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response is highly associated with chorioamnionitis,
bacterial infections to the fetuses and neonates are not
always evident. One of the reasons is that mycoplasma/
ureaplasma, which are common pathogens related to
preterm delivery (i.e. chorioamnionitis), are not detected
in a routine in-house bacterial culture and recently bacte-
rial genomic analysis has revealed that there are many
pathogens other than mycoplasma/ureaplasma that can
be associated with preterm delivery.22,23 We believe ‘sub-
clinical’ intra-amniotic infection may play a role, in part,
in the elevation of umbilical venous PCT.
We showed that the umbilical venous PCT level
had a strong correlation with the IL-6 level. All cases
with umbilical cord PCT levels of ≥170.0 pg/mL and
IL-6 levels of ≥11.0 pg/mL were in the CAM group.
Among 10 cases with umbilical venous PCT levels of
≥170.0 pg/mL and six cases with IL-6 levels of
≥11.0 pg/mL, six cases (60.0%) and five cases (83.3%),
respectively, had various adverse neonatal and infan-
tile outcomes, including chronic lung disease. This sug-
gests that similar to IL-6, the umbilical venous PCT
level can be a strong candidate for not only the predic-
tion of histological CAM, but also for the prediction of
adverse neonatal and infantile outcomes related to in
utero inflammation. Among seven cases with neonatal
and infantile adverse outcomes, one case was included
in the non-CAM group with low PCT and IL-6 levels.
The adverse neonatal and infantile outcomes, including
chronic lung diseases, necrotizing enterocolitis, and
periventricular leukomalacia, are attributed largely to
prenatal inflammation, but in part, to inflammation
during resuscitation, and postnatal inflammation
because of prematurity and circulatory instability after
birth. Therefore, in utero biomarkers, such as umbilical
venous PCT and IL-6 levels, cannot be used to make
predictions of adverse neonatal and infantile outcomes
in cases without any prenatal inflammation.
The limitation of this study was that it was retro-
spective, and the number of subjects was quite lim-
ited. However, we demonstrated that umbilical
venous PCT is a possible promising biomarker for
predicting adverse neonatal and infantile outcomes.
The selective treatment strategy based on inflamma-
tory status at birth using parameters including umbil-
ical venous PCT is expected to lead to an
improvement in neonatal/infantile outcome. This
study is only preliminary, and further prospective
studies are necessary to show the clinical usefulness
of umbilical venous PCT at birth.
In conclusion, in this study we found that the
umbilical venous PCT level was predictive of
histological CAM. Furthermore, the umbilical venous
PCT level suggested the possibility of predicting
adverse neonatal and infantile outcomes related to the
in utero inflammatory status.
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